Short term high dose @entity2993 for the prevention of @entity8 in XXXX undergoing computed tomography angiography.

@entity1 @entity8 @entity2993 @entity1011
BACKGROUND: Statins are shown effective by some studies in preventing @entity8 ( @entity8 ). We evaluated the effectiveness of @entity2993 in the prevention of @entity8 in computed tomography angiography (CTA) candidates. METHODS: This study was conducted on @entity1 referring for elective CTA with normal renal function. @entity1 received @entity2993 (80 mg/day) or placebo from 24 h before to 48 h after administration of the contrast material. Serum @entity1011 was measured before and 48 h after contrast material injection. @entity8 was defined as an increase in serum @entity1011 level of >=  0.5 mg/dl or >=  25% of the baseline @entity1011 . RESULTS: A total of 236 @entity1 completed the study; 115 @entity2993 , 121 placebo, mean age = 58.40    9.80 year, 68.6% male. Serum @entity1011 increased after contrast material injection in both the @entity2993 (1.00    0.16-1.02    0.15 mg/dl, P = 0.017) and placebo groups (1.03    0.17-1.08    0.18 mg/dl, P < 0.001). Controlling for age, gender, comorbidities, drug history, and baseline serum @entity1011 level, @entity1 who received @entity2993 experienced less increase in serum @entity1011 after contrast material injection (beta = 0.127, P = 0.034). However, there was no difference between the @entity2993 and placebo groups in the incidence of @entity8 (4.3 vs. 5.0%, P = 0.535). CONCLUSION: In @entity1 undergoing CTA, a short-term treatment with high dose @entity2993 is effective in preventing contrast-induced @entity8 , in terms of less increase in serum @entity1011 level after contrast material injection. Further trials including larger sample of @entity1 and longer follow-ups are warranted.
